The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. Its wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology. The company targets a large market opportunity with an estimated 57-77 million annual at-home agitation episodes in the U.S.
Cyborg Score Rationale
The company reported a net loss of $30.9 million for Q3 2025 with cash and equivalents of $37.3 million. An sNDA was submitted in January 2026 for at-home use with a revised market opportunity assessment. While clinical progress is positive, limited commercial revenue and cash constraints present near-term execution risks.
Top Insights
SERENITY At-Home Phase 3 trial enrolled 246 patients with no drug-related serious adverse events reported.
Q3 2025: IGALMI revenue $98k; operating loss $14.2M; cash $37.3M.
The company believes IGALMI could be approved as early as 2026 as an at-home treatment option.
The company returned to Nasdaq compliance on September 17, 2025.